Immunicon Corporation (IMMC) Receives Grant to Develop Test for Residual Disease in Leukemia Patients  
4/23/2008 9:39:16 AM

HUNTINGDON VALLEY, Pa.--(BUSINESS WIRE)--Immunicon Corporation (NASDAQ CM:IMMC) announced today that the company received a four-year grant from the Center for Translational Molecular Medicine (CTMM) to develop a test to detect minimal residual disease in blood of Acute Myeloid Leukemia patients. Using current methods, detection can only be done by taking regular bone marrow aspirates, which are typically very painful to extract for the patient. The program is planned to launch in September 2008 and is designed to broaden the number of personalized therapies available to patients.